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Background: Huntington’s Disease (HD) is a progressive neurodegenerative disorder caused by an expansion
in the polyglutamine (polyQ) region of the Huntingtin (HTT) gene. The clinical features of HD are characterized by
cognitive, psychological, and motor deficits. Molecular instability, a core component in neurological disease
progression, can be comprehensively evaluated through longitudinal transcriptomic profiling. Development of
animal models amenable to longitudinal examination enables distinct disease-associated mechanisms to
be identified.
Results: Here we report the first longitudinal study of transgenic monkeys with genomic integration of various
lengths of the human HTT gene and a range of polyQ repeats. With this unique group of transgenic HD nonhuman
primates (HD monkeys), we profiled over 47,000 transcripts from peripheral blood collected over a 2 year timespan
from HD monkeys and age-matched wild-type control monkeys.
Conclusions: Messenger RNAs with expression patterns which diverged with disease progression in the HD
monkeys considerably facilitated our search for transcripts with diagnostic or therapeutic potential in the blood of
human HD patients, opening up a new avenue for clinical investigation.
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HD is a dominant genetic disorder caused by pathologic
expansion of a polyglutamine (polyQ) repeat in exon
one of the IT15 gene encoding HTT. The hallmark of
HD is neurodegeneration and formation of mutant HTT
protein aggregates, predominantly in the striatum and
cerebral cortex [1]. The polyQ repeat length influences
the age of onset and the overall level of function, and
can be correlated with the severity of the disease [2].
However, it has been suggested that CAG length
accounted for 40% of the variability in the age of onset* Correspondence: awchan@emory.edu
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reproduction in any medium, provided the or[3], thus there are other factors which contribute to the
age of onset. The phenotype of the disease is demon-
strated through three categories of abnormalities: cogni-
tive, psychological, and motor. Studies have suggested
that cognitive deficits often emerge as the first symptom
of disease onset, specifically seen in speech delay in
juvenile HD patients [4]. Approximately 44% of HD pa-
tients experiencing some general cognitive impairment
reportedly struggle with memory retrieval [5]. The psy-
chiatric disorders common to HD include aggression,
affective disorders, irritability, obsession-like symptoms
and behavioral and personality disorders [6].
The average age of onset for HD is 37–38 years [7]
and the median life expectancy after disease onset is
16.2 years (with a span of 2–45), with the median being
similar regardless of age of onset [8]. Many patients have
children before discovering they have the disease.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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HD with very high penetrance, effective therapeutics
to treat disease symptoms remain elusive. Large se-
quencing or microarray profiling studies of the “trans-
criptome” (all RNA transcripts present in a species)
are beginning to facilitate identification of potential
new therapeutic targets in HD; however, extensive re-
search is required as humans generate thousands of
transcripts.
There are reports of RNA analysis from a range of
biological tissues types as well as from various model
systems with HD, including humans and rodents [9-12]
Transcript expression has been assessed from distinct
brain regions of HD patients [11,12], which is refining
our understanding of the molecular alterations with
disease progression. Although the brain is a primary
pathogenic target in HD, peripheral tissue damage is also
prevalent. Studies from peripheral cells which can non-
invasively be collected, such as blood, are ideal for longi-
tudinal correlation of transcriptome expression with the
stages of disease. Identified candidates from blood could
function as putative pathogenic biomarkers or thera-
peutic targets in pre- and post-symptomatic patients. To
date, there are limited reports of RNA analysis from
peripheral blood in HD, however, a few laboratories
have profiled mRNA alterations from total blood as
well as isolated lymphocytes [9,13]. The list of validated
targets from the blood cell studies are not expansive
and are cross-sectional analyses from only one species,
humans.
Here, we propose to elucidate the longitudinal trans-
criptomic patterns in peripheral blood of transgenic HD
monkeys, an animal model which has a long lifespan of
many years and are amenable to routine blood collection
[14]. Previous reports from our group have shown the
HD monkeys uniquely exhibit some symptoms consis-
tent with those exhibited in human patients [14]. We
developed a group of HD monkeys which express a frag-
ment of the human HTT gene with a range of polyQ
repeats greater than the 10–11 polyQ repeats that are
normally present in wild-type rhesus macaque. As rhe-
sus macaque endogenously express 10-11Q, the patho-
genic threshold of polyQ repeats in monkeys is expected
to be lower compared to 35–37 polyQ repeats in healthy
human populations [14]. Biological samples are collected
on a routine and scheduled basis throughout the lifespan
of each animal. We profiled the transcriptome of the
monkeys from peripheral blood and identified mRNAs
associated with HD during the first two-years of their
development, a timespan which encompasses the onset
of HD phenotype. We further monitored a select group
of candidates, based on their apparent corresponding
dysregulation reported in human HD patient blood, for
an additional year. Collectively, this study begins to mapthe molecular dynamics that occur during the course of
HD pathogenesis and identify transcriptomic targets
with distinct disease trends.Results
Generation of HD transgenic monkeys
Transgenic rhesus macaques were created to overexpress
exon 1 (rHD1) [14] or a larger fragment containing exons
1–10 of the human HTT gene (rHD6, rHD7 and rHD8),
under the control of the human polyubiquitin-C (UBC) or
human HTT promoter respectively, with different number
of polyQ repeats (Figure 1A and 1C). rHD1 expresses a
29Q repeat, and rHD6, rHD7, and rHD8 express 67Q,
70Q, and 72Q respectively (Figure 1C). All HD monkeys
carry HTT with expanded polyQ repeats, based on normal
wild-type rhesus macaque carry 10–11 polyQ repeats
(Additional file 1), which parallels the genetic anomalies
observed in human patients [15-18] (Figure 1A-1C).
Integrated polyQ repeat number varies among the HD
monkeys, which may be due to the inherent instability of
expanded polyQ sequences that has been extensively stud-
ied [19,20]. The UBC promoter permits more ubiquitous
expression of the transgene [14], whereas the HTT pro-
moter enables similar tissue-related expression patterns as
the endogenous HTT transcript [21,22]. Indeed, the endo-
genous HTT is not highly expressed in peripheral blood
[9,13], paralleling the lower levels of the transgene HTT
mRNA levels we observed in rHD6, rHD7 and rHD8
compared to rHD1, which is regulated by the UBC pro-
moter (Figure 1D). Based on our preliminary analysis of
rHD1 in its first 24 months of life, including imaging find-
ings, cognitive behavioral decline symptoms, and several
episodes of seizures at a young age (2 months), this
particular animal may parallel human juvenile onset HD
(JHD). On the other hand, the other three HD monkeys
that carry a larger HTT fragment driven by the human
HTT promoter seem to have a slower rate in progression
without the development of seizures; thus, these HD
monkeys may more closely resemble adult onset HD. We
developed an HD primate model rating scale (HDPMRS)
[14], which is modified from the Unified Huntington's
Disease Rating Scale (UHDRS) [23] that is commonly
used for monitoring progression of HD in patients. The
HDPMRS is primarily focused on monitoring the pro-
gression of motor deficit while psychological behaviors
such as suicidal thought and speech were excluded. All
HD monkeys exhibited progressive scores compared to
the control monkeys. At 12 months, there were no
apparent differences between the HD and control monkeys
by HDPMRS, however, at 24 months (5.25 vs 1; p < 0.05,
respectively) and 37 months (7 vs 1.75; P < 0.05, respec-
tively), the HD monkeys rated significantly above controls
(Additional file 2).
Figure 1 Molecular characterization of HD transgenic monkey founders. A) Schematic of lentiviral transgene for the generation of HD
monkeys. Primers used to genotype the HD monkeys are depicted in the schematics. B) Genotyping of HD monkeys using the primers outlined
in panel A. Expected PCR amplicon sizes are detailed in the table. Genotyping was performed using DNA extracted from blood samples of
individual founder and control monkeys. C) A table describing the promoter, transgene structure, copy number and number of polyQ repeat
units integrated into the genome of each HD monkey. All transgene copy number and polyQ analysis was examined in blood samples collected
from each monkey. D) Fold change of HTT mRNA expression by qPCR in all HD monkeys compared to age-matched controls from blood. The
qPCR for fold change analysis was set up in technical duplicates for each sample from the individual monkeys. The control group consists of the
values for all 4 wild-type monkeys.
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in HD monkeys
To systematically map the transcript expression patterns
with HD progression, we interrogated over 47,000 mRNAs
in peripheral blood samples collected from the HD mon-
keys and age-matched controls at 5, 11, 17 and 23 months
of age with rhesus macaque Affymetrix arrays. Spiking
controls present on the arrays showed very minimal differ-
ences across all hybridizations (not shown). We selected
32,617 out of 52,024 Rhesus Affymetrix probe sets on the
microarray for further analysis based on a “present” detec-
tion call from the Affymetrix MAS5 algorithm in 10% or
more of the samples (Additional file 3; currently in pro-
gress for GEO submission to NCBI). Two-way ANOVA of
log2-transformed probe intensities using a fixed-effect
model with disease as a categorical and age as a numeric
variable showed 1,521 and 3,341 probes with a significant
(p < 0.01 and false discovery rate (FDR) <0.1) disease and
age effect, respectively (Additional file 3, Figure 2A and 2B).
Significant pathway association with HD dysregulated
transcripts
Ingenuity analysis of the mRNAs with a P disease
value < 0.001 revealed 54 canonical pathways significantlyassociated with the dysregulated HD transcripts. Some of
those canonical pathways have previously been linked to
HD, such as pyruvate metabolism [24], glycolysis/gluco-
neogenesis [25], NGF signaling [26], and NRF2-mediated
Oxidative Stress Response [27] (Additional file 4).
Parallel disruption of transcript expression in HD monkey
and human blood
To identify mRNAs with the strongest potential for
association with HD, we compared the rhesus macaque
array data with array results deposited into the NCBI
GEO database from human blood of control and HD
patients [9]. For further stringency in our search for
HD-related transcripts, we analyzed two datasets depos-
ited into GEO from the same set of human samples
which were probed separately with two independent
array platforms (GEO files GDS1331 and GDS1332).
Between the two human array datasets (GDS 1331 and
1332), we identified 2850 mRNAs with analogous pat-
terns of disrupted transcript expression (P value < 0.05),
and focused on those for further comparison with the
rhesus candidates. Notably, 749 of the 2850 human HD
transcripts were also altered in our HD monkeys
(Figure 2C).
Figure 2 Genomic profiling of blood from developing HD monkeys. Total RNA from the peripheral blood was collected at 5, 11, 17, and
23 months and analyzed by Rhesus Macaque Affymetrix arrays. Histograms were generated from the array data. A) Probes with P-value and FDR
ranges from less than 1.0E-07 to greater than 1.0E-01 obtained from 2-way ANOVA for the effect of disease are plotted. 2-way ANOVA analysis
was from data spanning the 5, 11, 17, and 23 month samples. B) Probes with P-value and FDR ranges from less than 1.0E-07 to greater than
1.0E-01 obtained from 2-way ANOVA for the effect of age are plotted. C) Venn Diagram analysis of overlapping disease-associated mRNAs from
the HD monkeys with results from human HD patient blood deposited into the NCBI/GEO database. The human HD blood samples were
analyzed independently using two different array platforms (Affymetrix and Codelink) and compared with the rhesus HD-associated mRNAs by
Venn Diagram. All analyzed mRNAs have a P value < 0.05. D) The expression values (Log2 transformed & normalized microarray probeset
intensities) of 11 HD-associated mRNAs identified from the Rhesus profiling were median centered for heatmap analysis. Each column represent a
single sample, and each row represents a single mRNA probeset. Green squares represent lower than median levels of mRNA expression; black
squares represent median levels of mRNA expression; red squares represent higher than median levels of mRNA expression.
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dysregulation in human HD patients were graphed
individually to assess the disease-associated trend for each
gene and facilitate selection of mRNAs for further inves-
tigation. We selected a subset of 11 genes which displayed
a significant change in expression between HD and
controls across the timepoints analyzed by microarray of
5–23 months by Two-Way ANOVA (P disease < 0.05).
Those same candidates were also chosen based on their
corresponding dysregulation in studies from human con-
trol, presymptomatic and symptomatic HD patients (GEO
Database numbers 1331 and 1332) [9], which included;
Superoxide dismutase 2 (SOD2), frizzled family receptor 8
(FZD8), runt-related transcription factor 2 (RUNX2),
NADH dehydrogenase 1 alpha subcomplex 5 (NDUFA5),cell division cycle 25 homolog A (CDC25A), arachidonate
12-lipoxygenase (ALOX12), lamin A/C (LMNA), latexin
(LXN), AXL receptor tyrosine kinase (AXL), epsin 2
(EPN2), and tumor protein p63 (TP63) (Figure 2D,
Figure 3, Additional file 5, and Additional file 6). Among
the eleven candidates with significant changes, four can-
didates (FZD8, NDUFA5, LMNA, and RUNX2) also
displayed an age-effect in the array analysis (Figure 3).
Moreover, the 11 selected transcripts collectively encom-
pass a broad range of regulatory and signaling functions,
including mitochondrial and immune responses. Candi-
dates, including NDUFA5, ALOX12, LXN, EPN2, LMNA,
FZD8, and SOD2 began to display altered expression with
HD early in development, by 5 months of age (Figure 3).
Notably, those same candidates also exhibited an apparent
Figure 3 Longitudinal expression of disease-associated mRNAs from HD monkeys. The longitudinal trends for selected disease-associated
mRNAs from the HD monkeys, with parallel dysregulation in human HD blood, are plotted in panels A-K. All data represent raw fluorescence
units (log transformed) from the rhesus Affymetrix profiling results of white blood samples collected from 5, 11, 17, and 23 months for each of
the 4 control and 4 HD monkeys. The fluorescence values for all 4 controls were analyzed together and the values for all 4 HD monkeys were
analyzed together; one blood sample was analyzed per monkey per timepoint. All mRNA candidates have a disease-association P value of < 0.05
by 2-way ANOVA. A table of stats, including P values and FDRs for disease-association and age-effect by Two-Way ANOVA are outlined in panel L.
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HD patients, suggesting those transcripts may play a
role in the earlier stages of HD pathogenesis (Additional
file 5). The human study, however, is a cross-sectional
analysis, therefore, a full longitudinal study will help fur-
ther define the progression of molecular changes.Longitudinal transcriptomic analysis in HD monkeys by
real time PCR (qPCR)
To further examine transcriptome changes in the HD
monkeys, we measured all 11 mRNAs at extended
timepoints of 29, 32, and 39 months to validate the con-
tinuous longitudinal changes of the candidates (Figure 4,
Figure 4 Extended examination of HD-associated mRNAs by qPCR from blood of HD monkeys. Five of the selected HD-associated mRNA
transcripts with strong divergent trends (FZD8, NDUFA5, ALOX12, LMNA, LXN; panels A-E) were further subjected to evaluation by qPCR at
extended developmental timespans of 29, 32, and 39 months of age from all control and HD monkeys. Additionally, the 5, 11, 17, and 23 month
results timepoints for those same 5 candidates, initially examined by microarray, were also validated by qPCR. White blood cells were collected at
each timepoint, followed by RNA extraction and real-time PCR (qPCR) analysis with gene specific Taqman assays (Applied Biosystems). The
samples for qPCR were repeated in duplicates for each monkey. The values for all 4 controls were analyzed together and the values for all 4 HD
monkeys were analyzed together; one blood sample was analyzed per monkey per timepoint. All qPCR results were normalized with the
geometric mean of two endogenous controls, beta-actin (ACTB) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). A table of stats,
including P values and FDRs for disease-association and age-effect by Two-Way ANOVA with repeated measures are outlined in panel F.
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ALOX12, LXN, and LMNA) showed longitudinal statistical
dysregulation by two-way ANOVA from 5–39 months
(Figure 4F). Additionally, all 5 genes appeared to exhibit a
trend of altered expression at an early age, at least by
5 months; furthermore, NDUFA5 showed a trend of pro-
gressive dysregulation with age. Statistical comparison of
the slopes for the HD and control monkeys for NDUFA5
from 5 to 39 months revealed significantly different
trajectories (P value < 0.05 by Analysis of Covariance).Discussion
Here we report the first longitudinal transcriptomic pro-
filing study from an HD monkey model. HD is a highly
progressive disorder [28], therefore, identifying patterns
in mRNA expression which correspond with disease ad-
vancement will likely facilitate the development of novel
therapeutic strategies [29]. Distinct alterations in the HD
transcriptome were discovered during the first two years
of examination from peripheral blood. Some of the iden-
tified genes in this study, such as NDUFA5, are part ofthe canonical HD signaling pathway (KEGG pathway for
Huntington’s disease) [30], suggesting that alterations in
genes commonly associated with HTT-mediated patho-
genesis can be evaluated in peripheral blood. Moreover,
novel HD-associated mRNAs, such as LXN or FZD8, were
also identified through the correlation of HD monkey and
human profiles. Interestingly, LXN was previously shown
to be an important regulator of hematopoiesis [31-33],
while deficiencies in peripheral blood functions of HD
patients have been widely reported, including immune
responses [34-36]. Furthermore, the Wnt signaling cas-
cade, which FZD8 is a component of, is increasingly being
reported as an important regulator of the cellular res-
ponses to mHTT in HD [37-39]. Transcriptome changes
in human HD patients can be significantly influenced by
other co-existing pathology unrelated to HD, which argu-
ably would be a less pervasive influence in HD monkeys.
It would be anticipated, however, that the primary mo-
lecular targets of mHTT would be altered in both humans
and monkeys, in spite of other physiological or genetic
factors which might be present and non-specific to HD.
Overall, our data suggests the HD monkey model may help
Kocerha et al. BMC Neuroscience 2013, 14:88 Page 7 of 10
http://www.biomedcentral.com/1471-2202/14/88to uncover primate-associated transcriptomic changes due
to mHTT.
All five candidates we validated with disease associated
trends up to 39 months of age in the HD monkeys
(FZD8, LMNA, LXN, NDUFA5, and ALOX12) were
dysregulated at a very young age, presumbly in the earl-
ier stages of life based on HDPMRS, while other ongoing
clinical evaluations including cognitive behavior and
imaging studies will further define their phenotypes.
Genes with disrupted expression prior to onset of cogni-
tive and behavioral deficits could potentially be well
suited as therapeutic targets aimed to prevent deve-
lopment of disease symptoms. Furthermore, NDUFA5
appeared to also show a longitudinal escalation in tran-
script dysregulation with time and disease, suggesting it
may also serve as a blood biomarker for HD progression.
Interestingly, very recent reports indicate the mitochon-
drial respiratory chain, which NDUFA5 is part of, was
functionally impaired in platelets from pre-symptomatic
and symptomatic HD patients [40]. The upregulation of
NDUFA5 mRNA expression in the peripheral blood of
humans and monkeys with HD may represent a poten-
tial compensatory mechanism as pathology develops.
Although this study focused on samples with a mixed
population of WBC in both the monkey and human ana-
lysis, a future point of interest could entail examining
mRNA expression patterns in distinct classes of WBC as
well [13]. A cross-sectional study which profiled mRNAs
from lymphocytes has been reported (GEO file GDS2887)
[13], future longitudinal studies in HD primate models
focused on specific WBC cell types could help to further
define the location of the molecular changes.
Collectively, our data indicate that HD monkeys can be
a useful resource for uncovering transcriptomic targets
with correlation to disease progression. Furthermore,
longitudinal examination of disease-associated candidates
can be monitored from the blood of HD monkeys and
correlated with human HD patients for identification of
causative pathogenic pathways. Our results reporting
consistent molecular changes between HD monkeys and
human patients suggest the HD monkeys may be a poten-
tial model for future pre-clinical trials. Additionally, the
HD monkeys are not exposed to pharmacological agents,
thus preventing a drug-based bias in the longitudinal
studies.
As the HD monkeys further develop, future studies
will focus on extensive molecular mapping encompa-
ssing early to late stages of HD progression and define
which candidates may be optimal as biomarkers or as
therapeutic targets. Upcoming studies will also be able
to correlate transcriptomic changes with primate-
specific HD behavioral phenotypes, as well as other cli-
nical measurements [14]. Additionally, although the 11
candidates identified in this paper were significantlychanged with HD by microarray and extended longitu-
dinal analysis by qPCR, there is a possibility for gender
bias due to small sample size. In the current study, there
are 4 male HD monkeys and for the controls, there are 2
females and 2 males; thus, studies with future genera-
tions of HD monkeys can further examine any influence
of gender or other factors on the candidate gene ex-
pression. Recently, we reported germline transmission of
the human HTT transgene along with the presence of
pathogenic mHTT aggregation in neurons derived from
embryonic stem (ES) cells of rHD1 fertilized embryo
[41], setting the stage for creation of the next generation
of HD monkeys and corresponding studies.
Conclusions
We anticipate that on-going longitudinal studies in the
current group of HD monkeys as well as future genera-
tions will lead to a defined list of transcripts strongly
correlated with the progressive pathogenic stages in HD.
Future generations of HD monkeys can be engaged in
testing of novel pharmacological treatments, offering
new approaches to investigate HD.
Methods
Transgenic HD monkeys
We developed four transgenic HD monkeys, born and
raised at the Yerkes National Primate Research Center of
Emory University strictly following the IACUC protocols
for animal care. The control group was composed of two
females and two males, and the HD transgenic group
consisted of 4 males generated through a lentiviral-
mediated method as described by Yang and colleagues
[14]. In brief, lentiviruses carrying Exon 1 of the human
HTT gene (NCBI Reference Sequence: NM_002111.6)
containing 84 CAGs under the control of ubiquitin pro-
moter (LV-uHtt-84Q) and lentiviruses carrying Exon 1–10
of the human HTT gene containing 73Q under the control
of human HTT promoter (LV-hHtt-73Q) were used to
infect metaphase II arrested rhesus macaque oocytes
followed by fertilization and embryo transfer into surro-
gate females. The number of pathogenic polyQ repeats,
copy numbers of transgene per cell and general geno-
mic structure of transgene for each monkey are
outlined in Figure 1.
HD rating
Huntington’s disease primate model rating scale
(HDPMRS) is modified from the Unified Huntington’s
Disease Rating Scale (UHDRS) [23] to evaluate the pres-
ence and severity of motor symptoms that classically
accompany the disease (Additional file 8). The first section
of this battery is specific to the subject’s motor ability and
the second section serves as a functional assessment. The
HDPMRS is specifically to address motor symptoms of
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month for 30 minutes in a cage inside the room where the
animals were housed. Scoring of pre-recorded video was
performed by a neurologist specialized in movement
disorders who did not directly work with the animals,
while videos clips were only provided for scoring purpose.
T-Test was used to determine significant differences
between HD and control animals.
Blood collection and isolation of white blood cells (WBC)
Blood was collected and processed from all HD and
control monkeys at 6 month intervals of 5, 11, 17, and
23 months of age. In brief, the isolation of WBC utilized
gradient separation with lymphocyte separation media
(Lonza). The WBC containing layer from whole blood col-
lected in heparinized tubes was diluted with phosphate
buffered saline (PBS) and pipetted on top of the lym-
phocyte separation medium followed by centrifugation for
15 minutes at 20°C. After centrifugation, the interphase
containing the mononuclear WBC are removed and
washed twice with PBS prior to storage of pellet at −80°C.
Genotyping and polyQ analysis of HD monkeys from WBC
Genomic DNA (gDNA) was isolated from blood collected
from all HD monkeys for genotyping and sequence ana-
lysis. gDNA was extracted using the Promega Wizard kit
and quality was assessed by gel electrophoresis. Primers
for PCR amplification extended from the promoter to
beyond the polyQ region for all HD monkey transgene
analysis. Primer sequences for HD monkey rHD1, gene-
rated with pLV-uHtt-84Q, were Ubiquitin-F1 5′- GAG
GCG TCA GTT TCT TTG GTC -3′ and HDintron1-R
5′- GCT GGG TCA CTC TGT CTC TG -3′. Primer
sequences for HD monkeys (rHD6, rHD7, and rHD8) gen-
erated with pLV-hHtt-73Q, were: HTTproF6.5 5′- GTT
CTG CTT TTA CCT GCG GC -3′ and HDproexon4/5R
5′- CCG AGG GGC ACC ATT CTT TTT -3′. All reac-
tions were carried out with the annealing temperature of
62°C for 35 cycles in the BioRad iCycler. Amplified PCR
products were cloned into the pGEMT-easy vector
(Promega) and sequenced by Genewiz.
To obtain the relative copy number of mutant HTT
transgene in HD monkeys, gDNA was analyzed by qPCR
using two independent means of normalization for result
confirmation. First, using the HTTexon1 Taqman pri-
mers listed in Additional file 9, which recognizes both
the endogenous and transgene HTT, all reactions were
run in a final 1× volume of Fast Advanced Master Mix
(Applied Biosystems) and normalized to the geometric
mean of GAPDH and β-actin. The normalized Ct values
of each HD monkey were then compared to the average
of the normalized Ct values for the control monkeys. In
an independent experiment, we also normalized Ct
values obtained with the HTTexon1 Taqman primers withCt values using a Taqman assay designed to only recognize
the endogenous rhesus HTT gene (HTTexon26). The
exon1 Ct values of each HD monkey were normalized to
their exon26 Ct values and compared with the average of
the control monkeys.
For qPCR analysis of HTT mRNA expression from
blood, 750 ng of total RNA was reverse transcribed to
cDNA with the High Capacity Reverse Transcription Kit
(Applied Biosystems). Quantitation of HTT transcript
levels were evaluated by qPCR using a custom-designed
gene-specific Taqman assay (Applied Biosystems) and
reactions run on the BioRad CFX96 cycler (HTTexon1
Taqman assay in Additional file 9). All data were norma-
lized with the geometric mean of GAPDH and β-actin
with Taqman assays.
RNA isolation from WBC
For total RNA isolation from the WBC pellets collected
from the control and HD monkeys, we used a Trizol-
based protocol. Briefly, each WBC pellet was homogenized
in 500 μl of Trizol (Invitrogen). A phenol-chloroform
extraction of the RNA was done by addition of 100 μl of
chloroform to the Trizol homogenates followed by centri-
fugation at 12,000 × g for 10 minutes at 4°C. The aqueous
layer was removed for RNA precipitation overnight with
isopropanol and 40 μg of glycogen (Invitrogen) at −20°C.
The precipitated RNA was pelleted at 12,000 × g for
30 minutes at 4°C. All RNA pellets were washed twice
with 75% ethanol and then subsequently dissolved in
water (RNase/DNase free).
Affymetrix array profiling
In a longitudinal gene expression study, RNA from WBCs
of HD and control monkeys collected at four age-points
(5, 11, 17, and 23 months) were analyzed by using
Affymetrix Rhesus Macaque Genome arrays. All micro-
arrays and 2-way ANOVA statistical analysis was done at
Ocean Ridge Biosciences.
Biotin-labeled cRNA samples prepared from total
RNA using Affymetrix 3′ IVT Express Kit (PN 901229)
were hybridized onto the Rhesus Macaque Genome
arrays (PN 900655) for 16–18 hours. Scanned images of
the arrays were analyzed using RMA algorithm to export
the data CHP files using the Affymetrix Expression
Console software, version 1.1. Statistical analysis (2-way
ANOVA) was performed by dividing the samples into two
treatment groups (HD, CTRL) and four age-points (5, 11,
17, 23 months) using BRB-ArrayTools, version 4.1.
Detailed descriptions for the Affymetrix array methods
and analysis are further outlined in Additional file 10.
GEO database analysis for human blood
To compare the mRNA profile from the HD monkeys
with those from human HD patients, we analyzed
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deposited into the NCBI GEO database. The studies
consisted of WBC isolated from 14 controls and 12 symp-
tomatic HD patients and analyzed by both Affymetrix and
Codelink arrays (Geo files GDS1331 and GDS1332 res-
pectively). We calculated the fold change and P values for
each probeset from both the Affymetrix and Codelink
gene expression profiling. For added stringency, we identi-
fied mRNA candidates with similar dysregulation patterns
(P value ≤ 0.05) between the two sets of array data. The
genes with similar disruption between the two human
studies were then compared with the significant probesets
(P value ≤ 0.05 by two-way ANOVA) identified in our
array profiling results from the HD monkeys.mRNA candidate validation
For validation of selected mRNA candidates, 200 ng of
total RNA for each sample was reverse-transcribed to
cDNA using the High Capacity RNA to cDNA kit (Life
Technologies), following the manufacturer’s protocol. For
qPCR, 1 μl of cDNA was primed with custom-designed
Taqman assays from Applied Biosystems for the target
mRNA in a final reaction volume of 1× Taqman Universal
PCR Master Mix (Life Technologies). Primer sequences
for all Taqman assay primers and probes are listed in
Additional file 9.Additional files
Additional file 1: Wild-type rhesus macaque polyQ sequence. The
polyQ sequence from the UCSC genome database was further confirmed
and aligned with polyQ sequence from a wild-type rhesus housed at the
Yerkes National Primate Center.
Additional file 2: HD rating scores. HD rating scores by HDPMRS at
between 12 and 37 months for all HD and control monkeys.
Additional file 3: Microarray data. Raw fluorescence values for
each sample at each timepoint from the Affymetrix Rhesus Macaque
array analysis.
Additional file 4: Ingenuity analysis of HD monkey profiling results.
The Ingenuity pathway program was used to identify signaling pathways
(P value < 0.05) associated with HD mRNA transcripts dysregulated with
a P value < 0.001 in the Affymetrix profiling.
Additional file 5: Human HD candidate graphs. Eleven selected
transcripts from human HD blood array data (obtained from the GEO
database) were graphed from control, pre-symptomatic, and post-
symptomatic patient samples.
Additional file 6: Human HD array probeset information. The
human array probeset information for the selected HD-associated
candidates.
Additional file 7: qPCR expression analysis of selected HD
mRNA candidates at extended timepoints. The mRNA expression
of eleven candidates with HD association in monkey and human
blood were analyzed at additional timepoints of 29, 32, and
39 months.
Additional file 8: HD Rating Scale. Parameters measured in the HD
primate rating scale.Additional file 9: Rhesus Taqman assay information. All forward,
reverse, and probe sequences for rhesus Taqman assays engaged for this
manuscript.
Additional file 10: Microarray methods. Additional information
regarding the Rhesus Macaque Affymetrix profiling are outlined.
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